Effect of TGF-β1 antisense S-oligonucleotide on synthesis and accumulation of matrix proteoglycans in balloon catheter-injured neointima of rabbit carotid arteries

Journal of Vascular Research

Volumn 37, Issue 1, 2000, Pages 50-60

  Merrilees, Mervyn J ^a   Beaumont, Brent ^a   Scott, Lesley ^a   Hermanutz, Valentin ^a   Fennessy, Paul ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antisense; Neointima; Proteoglycans; Transforming growth factor 1; Versican

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA ACTIN; BIGLYCAN; CYCLINE; DECORIN; GLUCOSAMINE; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEOGLYCAN; TRANSFORMING GROWTH FACTOR BETA1; VERSICAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON CATHETER; CAROTID ARTERY; CONTROLLED STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEOGLYCAN SYNTHESIS; RABBIT;

EID: 0034061747     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000025713     Document Type: Article

References (40)

1. Wight T: The extracellular matrix and atherosclerosis. Curr Opin Lipidol 1995;6:326-334.
2. Scott L, Kerr A, Haydock D, Merrilees M: Subendothelial proteoglycan synthesis and transforming growth factor beta distribution correlate with susceptibility to atherosclerosis. J Vasc Res 1997;34:365-377.
3. Chen J-K, Hoshi H, McKechan WL: Transforming growth factor type β specifically stimulates synthesis of proteoglycan in human adult arterial smooth muscle cells. Proc Natl Acad Sci USA 1987;84:5287-5291.
4. Bassols A, Massague J: Transforming growth factor β regulates the expression and structure of extracellular matrix chondroitin/dermatan sulfate proteoglycans. J Biol Chem 1988;263: 3039-3045.
5. Merrilees MJ, Scott L: Endothelial cell stimulation of smooth muscle glycosaminoglycan synthesis can be accounted for by transforming growth factor beta activity. Atherosclerosis 1990;81:255-265.
6. Merrilees MJ, Scott L: Antisense S-oligonucleotide against TGF-β1 inhibits proteoglycan synthesis in arterial wall. J Vasc Res 1994;31: 322-329.
7. 1, during repair of arterial injury. J Clin Invest 1991;88:904-910.
8. Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, Wier L: Expression of transforming growth factor-β1 is increased in human vascular restenosis lesions. J Clin Invest 1992;90: 1582-1592.
9. 1 in rabbit arteries injured with a balloon catheter. Arterioscler Thromb Vasc Biol 1995;15:1951-1957.
10. Nabel EG, Shum L, Pompili VJ, Yang ZY, San H, Shu HB, Liptay S, Gold L: Direct transfer of transforming growth factor β1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA 1993;90:10759-10763.
11. 1 suppress intimal hyperplasia in a rat model. J Clin Invest 1994;93:1172-1178.
12. Koyama H, Reidy MA: Expression of extracellular matrix proteins accompanies lesion growth in a model of intimal reinjury. Circ Res 1998;82:988-995.
13. Smith JD, Bryant Sr, Couper LL, Vary CPH, Gotwals PJ, Koteliansky VE, Lindner V: Soluble transforming growth factor-b type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res 1999; 84:1212-1222.
14. Riessen R, Isner JM, Blessing E, Loushin C, Nikol S, Wight TN: Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic arteries. Am J Pathol 1994;144:962-974.
15. Lopez-Candales A, Scott MJ, Wickline S: Cholesterol feeding modulates spatial expression of TGF-β1 and β2 in aortas of Watanabe rabbits. Cytokine 1995;7:554-561.
16. Kahari VM, Larjava H, Uitto J: Differential regulation of extracellular matrix proteoglycan gene expression. J Biol Chem 1991;266:10608-10615.
17. Schönherr E, Jarvelainen HT, Kinsella MG, Sandell LJ, Wight TN: Platelet-derived growth factor and transforming growth factor-β differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells. Arterioscler Thromb 1993;13:1026-1036.
18. Stary HC: The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. Eur Heart J 1990;11(suppl E):3-19.
19. Riessen R, Isner JM, Blessing E, Loushin C, Nikol S, Wight TN: Regional differences in the distribution of the proteoglycans biglycan and decorin in extracellular matrix of atherosclerotic and restenotic human coronary arteries. Am J Pathol 1994;144:962-974.
20. Wight TN, Lara S, Riessen R, Le Baron R, Isner J: Selective deposits of versican in the extracellular matrix of restenotic lesions from human peripheral arteries. Am J Pathol 1997; 151:963-973.
21. Evanko SP, Raines EW, Ross R, Gold LI, Wight TN: Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-β. Am J Pathol 1998;152: 533-546.
22. Lin H, Wilson JE, Roberts CR, Horley KJ, Winters GL, Costanzo MR, McManus BM: Biglycan, decorin, and versican protein expression patterns in coronary arteriopathy of human cardiac allografts: Distinctness as compared to native atherosclerosis. J Heart Lung Transplant 1996;15:1233-1247.
23. Robbins JR, Evanko SP, Vogel KG: Mechanical loading and TGF-β regulate proteoglycan synthesis in tendon. Arch Biochem Biophys 1997;342:203-211.
24. Villa AE, Guzman LA, Poptic EJ, Labhasetwar V, D'Souza S, Farrell CL, Plow EF, Levy RJ, DiCorleto PE, Topol EJ: Effects of antisense c-myb olignoucleotidcs on vascular smooth muscle cell proliferation and response to vessel wall injury. Circ Res 1995;76:505-513.
25. Wang W, Chen HJ, Schwartz A, Cannon PJ, Stein CA, Rabbani LE: Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligonucleotides. J Clin Invest 1996;98:443-450.
26. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA: Phosphorothioate oligonucleotides bind to basic fibrolast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on the extracellular matrix. J Biol Chem 1995;270:2620-2627.
27. Khaled Z, Benimetskaya I, Zeltser R, Khan T, Sharma HW, Narayanan R, Stein CA: Multiple mechanisms may contribute to the cellular antiadhesive effects of phosphorothioate oligonucleotides. Nucleic Acids Res 1996;24:737-745.
28. Bennett MR, Schwartz SM: Antisense therapy for angioplasty restenosis: Some critical considerations. Circulation 1995;92:1981-1993.
29. Hansson GK, Jonasson L, Holm J, Clowes MM, Clowes AW: γ-Interferon regulates vascular smooth muscle cell proliferation and la antigen expression in vivo and in vitro. Circ Res 1988;63:712-719.
30. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ: Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993;90:8474-8478.
31. Morishita R, Gibbons GH, Ellison KE, Nakajima M, von der Leyen H, Zhang L, Kaneda Y, Ogihara T, Dzau VJ: Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest 1994;93: 1458-1464.
32. Abe J, Zhou W, Taguchi J, Takuwa N, Miki K, Okazaki H, Kurokawa K, Kumada M, Takuwa Y: Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. Biochem Biophys Res Commun 1994;198:16-24.
33. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB, Karin M, Roberts AB: Autoinduction of TGF-β1 is mediated by the AP-1 complex. Mo1 Cell Biol 1990;10:1492-1497.
34. Border WA, Nobel NA: Transforming growth factor-β in tissue fibrosis. N Engl J Med 1992; 331:1286-1292.
35. Yamagata M, Kimata K: Repression of a malignant cell-substratum adhesion phenotype by inhibiting the production of the anti-adhesive proteoglycan, PM-M/versican. J Cell Sci 1994; 107:2581-2590.
36. Zhang Y, Cao L, Yang BL, Yang BB: The G3 domain of versican enhances cell proliferation via epidermal growth factor-like motifs. J Biol Chem 1998;273:21342-21351.
37. Camejo G, Hurt-Camejo E, Olsson U, Bondjers G: Proteoglycans and lipoproteins in atherosclerosis. Curr Opin Lipidol 1993;4:385-391.
38. Williams KJ, Tabas I: The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995;15:551-561.
39. O'Brien K, Olin K, Alpers CE, Chin W, Ferguson M, Hudkins K, Wight TN, Chait A: A comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: Co-localization of biglycan and apolipoproteins. Circulation 1998;98:519-527.
40. Boren J, Olin KL, Lee I, Chait A, Wight T, Innerarity TL: Identification of the principal proteoglycan-binding site in LDL: A single point mutation in apolipoprotein B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J Clin Invest 1998;101:2658-2664.